We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Testing Device Integrates Robotic Phlebotomy with Sample Processing

By LabMedica International staff writers
Posted on 20 Jun 2018
Diagnostic blood testing is the most commonly performed clinical procedure in the world and influences the majority of medical decisions made in hospital and laboratory settings. More...
However, manual blood draw success rates are dependent on clinician skill and patient physiology.

Results from such tests are generated almost exclusively in centralized laboratories from large-volume samples using labor-intensive analytical techniques. An end-to-end blood-testing device has been developed that integrates robotic phlebotomy with downstream sample processing. This platform device performs blood draws and provides diagnostic results in a fully automated fashion at the point-of-care.

Biomedical engineers at Rutgers University, Piscataway NJ, USA) created a device that includes an image-guided venipuncture robot, to address the challenges of routine venous access, with a centrifuge-based blood analyzer to obtain quantitative measurements of hematology. The team first demonstrated a white blood cell assay on the analyzer, using a blood mimicking fluid spiked with fluorescent microbeads, where the area of the packed bead layer is correlated with the bead concentration. Next the scientists performed studies to evaluate the pumping efficiency of the sample-handling module. Finally, studies were conducted on the integrated device from blood draw to analysis, using blood vessel phantoms to assess the accuracy and repeatability of the resulting white blood cell assay.

Martin Yarmush, MD, PhD, a Distinguished Professor of Biomedical Engineering and the senior author of the study said, “This device represents the holy grail in blood testing technology. Integrating miniaturized robotic and microfluidic systems, this technology combines the breadth and accuracy of traditional laboratory testing with the speed and convenience of point-of-care testing.” The study was published on May 30, 2018, in the journal Technology.

Related Links:
Rutgers University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The test combines RNA signals from the tumor-immune microenvironment to predict treatment response, rather than relying on a single marker such as PD-L1 expression.(Image Credit: Adobe Stock)

RNA-Based Test Predicts Immunotherapy Response in Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) represents the largest U.S. patient population eligible for immune checkpoint inhibitor therapy. Treatment selection often relies on PD-L1 expression, but a single protein... Read more

Immunology

view channel
Image Credit: Adobe Stock

Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk

A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more

Industry

view channel
Image Credit: iStock

Global TB Summit Connects Diagnostic Testing With Prevention and Clinical Care

Tuberculosis remains a major global infectious disease challenge despite declining deaths. In 2024, an estimated 10.7 million people worldwide developed the disease and nearly 1.2 million died from it.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.